We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App


13 Jun 2024 - 15 Jun 2024
18 Jun 2024 - 20 Jun 2024

Minimally Invasive Technique Demonstrates Positive Surgical Outcome in Treatment of Hemorrhagic Strokes

By HospiMedica International staff writers
Posted on 27 Apr 2023
Print article
Image: The BrainPath family of products includes 13.5mm and 11mm diameter devices of various lengths (Photo courtesy of NICO)
Image: The BrainPath family of products includes 13.5mm and 11mm diameter devices of various lengths (Photo courtesy of NICO)

Annually, hemorrhagic strokes affect two million people, representing the most lethal, expensive, and debilitating type of stroke. This kind of stroke occurs when a weakened blood vessel ruptures and bleeds into the brain, causing toxic blood to accumulate. Regrettably, nearly 50% of hemorrhagic stroke victims die within a month. Studies indicate that removing blood from the brain within 24 hours of the bleeding onset could minimize brain damage and fatalities. Currently, the standard treatment involves administering medication or adopting a "watch and see" approach, potentially prolonging blood presence in the brain and raising the risk of complications. Researchers have now announced promising results from a surgical treatment trial for hemorrhagic strokes, showing positive outcomes in treating intracerebral hemorrhage (ICH).

In the ENRICH (Early MiNimally-invasive Removal of ICH) randomized, multi-center clinical trial led by Emory University School of Medicine (Atlanta, GA, USA), researchers compared standard medical management to early minimally invasive parafascicular surgery (MIPS) using the BrainPath and Myriad technology from NICO Corporation (Indianapolis, IN, USA). The BrainPath device assists surgeons in reaching the bleeding site in the brain by delicately navigating through its folds and fibers, gently displacing brain tissue to create a pathway. Once at the site, the Myriad device, an automated suction and resection tool, removes the clot.

After six months, functional outcomes in ENRICH were assessed using the utility-weighted modified Rankin Scale (UWmRS), with scores above zero indicating improved results. The mean UWmRS score was 0.458 for the MIPS group and 0.374 for those receiving standard medical management, reflecting a 98.1% posterior probability of superiority. This difference fulfilled the primary endpoint, proving a statistically significant and clinically meaningful improvement in UWmRS for the MIPS group. The ENRICH study also determined MIPS to be safe, with an overall mortality rate of 21.7% at six months (20% for MIPS, 23.3% for the standard medical management group). In the MIPS group, median hematoma evacuation was 88%, with a median end-of-treatment volume (EOTV) of 7.2mL. Overall, 73% of patients achieved the EOTV goal of less than 15mL, considered the surgical standard in clot evacuation.

“The results of the ENRICH trial are revolutionary and represent an advancement for improving outcomes for the millions of people who suffer hemorrhagic strokes,” said Jim Pearson, president and CEO, NICO Corporation.

“ENRICH is the first, randomized clinical trial to meet its primary endpoint, while improving outcomes for these deadly strokes,” said Gustavo Pradilla, MD, co-lead investigator for ENRICH, associate professor of neurosurgery at Emory University School of Medicine and chief of neurosurgery for Grady Memorial Hospital. “This trial will help to change how we treat hemorrhagic stroke moving forward.”

Related Links:
Emory University School of Medicine 
NICO Corporation 

Gold Member
Solid State Kv/Dose Multi-Sensor
Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Silver Member
Wireless Mobile ECG Recorder
Fiberoptic Laryngoscope Set

Print article


Surgical Techniques

view channel
Image: The researchers tweaked borophene to interact with cells and other biological units in unique ways (Photo courtesy of Dipanjan Pan/Penn State)

New Two-Dimensional Material Paves Way for Safer, More Effective Implantable Medical Devices

Borophene, first synthesized in 2015, is an atomically thin version of boron that surpasses graphene—the two-dimensional (2D) version of carbon—in conductivity, thinness, lightness, strength, and flexibility.... Read more

Patient Care

view channel
Image: The portable, handheld BeamClean technology inactivates pathogens on commonly touched surfaces in seconds (Photo courtesy of Freestyle Partners)

First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds

Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The Quantra Hemostasis System has received US FDA special 510(k) clearance for use with its Quantra QStat Cartridge (Photo courtesy of HemoSonics)

Critical Bleeding Management System to Help Hospitals Further Standardize Viscoelastic Testing

Surgical procedures are often accompanied by significant blood loss and the subsequent high likelihood of the need for allogeneic blood transfusions. These transfusions, while critical, are linked to various... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.